Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma

NCT01271504 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01271504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01271504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 19, 2011
Completion date
June 23, 2015
Enrollment
102 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma